The earnings call reflected a generally positive sentiment with notable growth in sequential revenue, wholesale and retail operations, and successful expansion into new markets like Delaware and Pennsylvania. However, challenges such as year-over-year revenue decline, performance issues in Missouri, and competition affecting the Metropolis dispensary were also highlighted.

Company Guidance

During the MariMed Inc. Second Quarter 2025 Financial Results Conference Call, the company reported a sequential revenue increase of 4.4% to $39.6 million, although it was a 2% decline year-over-year. Wholesale revenue grew by 2% sequentially and 8% year-over-year, with Massachusetts showing a significant 5.6% increase. Retail revenue also increased by 8% sequentially, despite a 5% year-over-year decline, primarily due to competition near their Metropolis dispensary. MariMed's adjusted gross margin was 41.9%, slightly up from the previous quarter. The company reported a net loss of $1.3 million, an improvement from both the previous quarter and the same period last year. Adjusted EBITDA rose to $4.9 million, driven by increased revenue and cost management. The balance sheet remained strong with $6.1 million in cash and $38.5 million in operating working capital. The company highlighted its strategic moves, such as the expansion of adult-use sales in Delaware and entry into Pennsylvania, as key growth drivers for the future.

Sequential Revenue Growth

Consolidated revenue for the second quarter of 2025 was $39.6 million, representing a 4.4% increase sequentially.

Wholesale Revenue Growth

Wholesale revenue grew 2% sequentially and 8% compared to the same period last year.

Retail Revenue Growth

Retail revenue increased 8% sequentially, driven by growth in top line across most dispensaries.

Adjusted EBITDA Increase

Adjusted EBITDA for the second quarter was $4.9 million, an increase of $2.3 million sequentially.

Adult-Use Sales in Delaware

MariMed was ready to take full advantage of adult-use sales beginning in Delaware, contributing to increased growth at both retail and wholesale levels.

Expansion into Pennsylvania

MariMed entered into an MSA agreement to manage a cultivation and processing facility in Pennsylvania, which is expected to contribute to top line and margins starting September 1.

Brand Performance

Betty's Eddies remained the top-selling edible in Massachusetts, Maryland, and Delaware, and Vibations performed well, being a top 10 brand in core markets.

Cash Flow Positive

MariMed was cash flow positive, ending the quarter with $6.1 million in cash and cash equivalents.

MariMed (MRMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MRMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.01 / -	0.004	―	―	―
Aug 06, 2025	2025 (Q2)	-0.01 / 0.00	-0.001	―	―
May 07, 2025	2025 (Q1)	-0.01 / -0.01	0	―	―
Mar 05, 2025	2024 (Q4)	-0.01 / -0.02	0.001	-2100.00% (-0.02)	―
Nov 06, 2024	2024 (Q3)	-0.01 / <0.01	-0.01	140.00% (+0.01)	―
Aug 07, 2024	2024 (Q2)	-0.01 / >-0.01	0.002	-150.00% (>-0.01)	―
May 08, 2024	2024 (Q1)	-0.01 / 0.00	0.001	―	―
Mar 06, 2024	2023 (Q4)	0.00 / <0.01	0.01	-90.00% (>-0.01)	―
Nov 08, 2023	2023 (Q3)	>-0.01 / -0.01	0.01	-200.00% (-0.02)	―
Aug 02, 2023	2023 (Q2)	0.00 / <0.01	0	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MRMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$0.11	$0.10	-9.09%
May 07, 2025	$0.10	$0.10	0.00%
Mar 05, 2025	$0.12	$0.11	-8.33%
Nov 06, 2024	$0.15	$0.15	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Marimed (MRMD) report earnings?

Marimed (MRMD) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Marimed (MRMD) earnings time?

Marimed (MRMD) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MRMD EPS forecast?

MRMD EPS forecast for the fiscal quarter 2025 (Q3) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing